Kadcyla breast cancer drug

Rights Managed

SS2762534

SV1668

Kadcyla breast cancer drug. Packet of the anti-cancer drug trastuzumab emtansine, marketed by Roche under the trade name Kadcyla. This drug is an antibody-drug conjugate (ADC) with an antibody linked to a drug that kills the cancer cells targeted by the antibody. In this case, the conjugate is of trastuzumab (Herceptin) linked to the cytotoxic chemical mertansine (DM1). Herceptin targets the HER2 receptor in breast cancer. Trastuzumab emtansine was developed by Genentech and approved for use in the USA in 2013. Photographed in 2014.

Dr. P. Marazzi / Science Source